600216 浙江醫藥
按盤價 
10.190 +0.430 (+4.406%) | 2024/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 2,249,164 | 12.01% | 7,794,146 | 8,115,805 | 9,129,094 | 7,326,935 | |
| 減：營業總成本 | 2,131,385 | 12.03% | 7,681,666 | 7,482,025 | 7,932,301 | 6,516,358 | |
| 其中:營業成本 | 1,508,814 | 13.43% | 5,269,879 | 5,318,274 | 5,399,736 | 4,283,391 | |
| 財務費用 | 2,007 | -82.47% | (17,488) | (37,966) | 93,110 | 70,066 | |
| 資產減值損失 | (26,260) | 92.87% | (137,208) | (117,141) | (165,169) | (129,541) | |
| 公允價值變動收益 | (6,963) | -161.57% | (10,099) | (23,881) | 51,726 | 30,477 | |
| 投資收益 | (1,501) | -148.12% | (3,505) | (32,626) | 41,815 | 119,744 | |
| 其中：對聯營企業和合營企業的投資收益 | (845) | -50.16% | (9,782) | (3,806) | (4,240) | (648) | |
| 營業利潤 | 101,798 | -3.33% | 380,158 | 504,616 | 1,179,437 | 882,635 | |
| 利潤總額 | 101,044 | -1.29% | 363,279 | 491,388 | 1,153,532 | 850,981 | |
| 減：所得稅費用 | 21,681 | 18.54% | 86,485 | 128,775 | 268,972 | 191,336 | |
| 淨利潤 | 79,363 | -5.60% | 276,794 | 362,614 | 884,559 | 659,645 | |
| 減：非控股權益 | (30,286) | 2.74% | (152,845) | (176,956) | (160,763) | (57,755) | |
| 股東淨利潤 | 109,650 | -3.44% | 429,640 | 539,570 | 1,045,322 | 717,400 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.110 | -8.33% | 0.450 | 0.560 | 1.090 | 0.750 | |
| 每股派息 (元) * | -- | -- | 0.150 | 0.170 | 0.330 | 0.230 | |
| 每股淨資產 (元) * | 10.092 | 3.60% | 9.980 | 9.594 | 9.096 | 7.952 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 21/06/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
